Iñigo Martincorena

Iñigo Martincorena

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Iñigo Martincorena

Wellcome Sanger Institute, Hinxton, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Cell
Verified
Journal Article
Open access
IMIñigo Martincorena
Iñigo Martincorena
KRKeiran M. Raine
Keiran M. Raine
MGMoritz Gerstung
Moritz Gerstung
KDKevin J. Dawson
Kevin J. Dawson
KHKerstin Haase
Kerstin Haase
PCPeter J. Campbell
Peter J. Campbell
Cancer develops as a result of somatic mutation and clonal selection, but quantitative measures of selection in cancer evolution are lacking. We adapted methods from molecular evolution and applied them to 7,664 tumors across 29 cancer types. Unlike species evolution, positive selection outweighs negative selection during cancer development. On average, 10/tumor in endometrial and colorectal cancers. Half of driver substitutions occur in yet-to-be-discovered cancer genes. With increasing mutation burden, numbers of driver mutations increase, but not linearly. We systematically catalog cancer genes and show that genes vary extensively in what proportion of mutations are drivers versus passengers.

23 November 2018 in Science
Verified
Journal Article
Closed access
PDF file
IMIñigo Martincorena
Iñigo Martincorena
JFJoanna C. Fowler
Joanna C. Fowler
AWAgnieszka Wabik
Agnieszka Wabik
ALAndrew R. J. Lawson
Andrew R. J. Lawson
FAFederico Abascal
Federico Abascal
PJPhilip H. Jones
Philip H. Jones
The mutational burden of aging: As people age, they accumulate somatic mutations in healthy cells. About 25% of cells in normal, sun-exposed skin harbor cancer driver mutations. What about tissues not exposed to powerful mutagens like ultraviolet light? Martincorenaet al.performed targeted gene sequencing of normal esophageal epithelium from nine human donors of varying age (see the Perspective by Chanock). The mutation rate was lower in esophagus than in skin, but there was a strong positive selection of clones carrying mutations in 14 cancer-associated genes. By middle age, more than half of the esophageal epithelium was colonized by mutant clones. Interestingly, mutations in the cancer driver geneNOTCH1were more common in normal esophageal epithelium than in esophageal cancer.Science, this issue p.911; see also p.893

5 February 2020 in Nature
Verified
Journal Article
Open access
PDF file
EREsther Rheinbay
Esther Rheinbay
MNMorten Muhlig Nielsen
Morten Muhlig Nielsen
FAFederico Abascal
Federico Abascal
JWJeremiah A. Wala
Jeremiah A. Wala
OSOfer Shapira
Ofer Shapira
GGGad Getz
Gad Getz
The discovery of drivers of cancer has traditionally focused on protein-coding genes1–4. Here we present analyses of driver point mutations and structural variants in non-coding regions across 2,658 genomes from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium5 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). For point mutations, we developed a statistically rigorous strategy for combining significance levels from multiple methods of driver discovery that overcomes the limitations of individual methods. For structural variants, we present two methods of driver discovery, and identify regions that are significantly affected by recurrent breakpoints and recurrent somatic juxtapositions. Our analyses confirm previously reported drivers6,7, raise doubts about others and identify novel candidates, including point mutations in the 5′ region of TP53, in the 3′ untranslated regions of NFKBIZ and TOB1, focal deletions in BRD4 and rearrangements in the loci of AKR1C genes. We show that although point mutations and structural variants that drive cancer are less frequent in non-coding genes and regulatory sequences than in protein-coding genes, additional examples of these drivers will be found as more cancer genomes become available.

1 June 2022 in Nature
Verified
Journal Article
Open access
PDF file
EMEmily Mitchell
Emily Mitchell
MCMichael Spencer Chapman
Michael Spencer Chapman
NWNicholas Williams
Nicholas Williams
KDKevin J. Dawson
Kevin J. Dawson
NMNicole Mende
Nicole Mende
PCPeter J. Campbell
Peter J. Campbell
Age-related change in human haematopoiesis causes reduced regenerative capacity1, cytopenias2, immune dysfunction3 and increased risk of blood cancer4–6, but the reason for such abrupt functional decline after 70 years of age remains unclear. Here we sequenced 3,579 genomes from single cell-derived colonies of haematopoietic cells across 10 human subjects from 0 to 81 years of age. Haematopoietic stem cells or multipotent progenitors (HSC/MPPs) accumulated a mean of 17 mutations per year after birth and lost 30 base pairs per year of telomere length. Haematopoiesis in adults less than 65 years of age was massively polyclonal, with high clonal diversity and a stable population of 20,000–200,000 HSC/MPPs contributing evenly to blood production. By contrast, haematopoiesis in individuals aged over 75 showed profoundly decreased clonal diversity. In each of the older subjects, 30–60% of haematopoiesis was accounted for by 12–18 independent clones, each contributing 1–34% of blood production. Most clones had begun their expansion before the subject was 40 years old, but only 22% had known driver mutations. Genome-wide selection analysis estimated that between 1 in 34 and 1 in 12 non-synonymous mutations were drivers, accruing at constant rates throughout life, affecting more genes than identified in blood cancers. Loss of the Y chromosome conferred selective benefits in males. Simulations of haematopoiesis, with constant stem cell population size and constant acquisition of driver mutations conferring moderate fitness benefits, entirely explained the abrupt change in clonal structure in the elderly. Rapidly decreasing clonal diversity is a universal feature of haematopoiesis in aged humans, underpinned by pervasive positive selection acting on many more genes than currently identified.

28 April 2021 in Nature
Verified
Journal Article
Closed access
PDF file
FAFederico Abascal
Federico Abascal
LHLuke M. R. Harvey
Luke M. R. Harvey
EMEmily Mitchell
Emily Mitchell
ALAndrew R. J. Lawson
Andrew R. J. Lawson
SLStefanie V. Lensing
Stefanie V. Lensing
IMIñigo Martincorena
Iñigo Martincorena

13 April 2022 in Nature
Verified
Journal Article
Open access
PDF file
ACAlex Cagan
Alex Cagan
ABAdrian Baez-Ortega
Adrian Baez-Ortega
NBNatalia Brzozowska
Natalia Brzozowska
FAFederico Abascal
Federico Abascal
TCTim H. H. Coorens
Tim H. H. Coorens
IMIñigo Martincorena
Iñigo Martincorena
The rates and patterns of somatic mutation in normal tissues are largely unknown outside of humans1–7. Comparative analyses can shed light on the diversity of mutagenesis across species, and on long-standing hypotheses about the evolution of somatic mutation rates and their role in cancer and ageing. Here we performed whole-genome sequencing of 208 intestinal crypts from 56 individuals to study the landscape of somatic mutation across 16 mammalian species. We found that somatic mutagenesis was dominated by seemingly endogenous mutational processes in all species, including 5-methylcytosine deamination and oxidative damage. With some differences, mutational signatures in other species resembled those described in humans8, although the relative contribution of each signature varied across species. Notably, the somatic mutation rate per year varied greatly across species and exhibited a strong inverse relationship with species lifespan, with no other life-history trait studied showing a comparable association. Despite widely different life histories among the species we examined—including variation of around 30-fold in lifespan and around 40,000-fold in body mass—the somatic mutation burden at the end of lifespan varied only by a factor of around 3. These data unveil common mutational processes across mammals, and suggest that somatic mutation rates are evolutionarily constrained and may be a contributing factor in ageing.